[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363794-105":59,"doc-detail-363794-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","elecla-trial-final-results-of-perioperative-chemotherapy-with-fluoropyrimidine-and-oxaliplatin-in-mismatch-repair-proficient-locally-advanced-colon-cancer","ELECLA trial - final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer","","A multicenter randomized phase II ELECLA trial evaluates neoadjuvant chemotherapy in radiologically defined locally advanced colon cancer with proficient mismatch repair status. Patients received either neoadjuvant chemotherapy (CAPOX or FOLFOX) followed by surgery and adjuvant chemotherapy or upfront surgery followed by adjuvant chemotherapy. The primary endpoint was 2-year disease-free survival. Among 120 patients, NAC completion reached 94.2% with improved tumor downstaging and favorable pathologic features, without increased perioperative morbidity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/elecla-trial-final-results-of-perioperative-chemotherapy-with-fluoropyrimidine-and-oxaliplatin-in-mismatch-repair-proficient-locally-advanced-colon-cancer/363794/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/elecla-trial-final-results-of-perioperative-chemotherapy-with-fluoropyrimidine-and-oxaliplatin-in-mismatch-repair-proficient-locally-advanced-colon-cancer/363794.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the ELECLA trial designed to assess in locally advanced colon cancer?","Question",{"text":113,"@type":114},"It evaluated the safety and efficacy of neoadjuvant chemotherapy versus upfront surgery followed by adjuvant chemotherapy in radiologically defined locally advanced colon cancer with proficient mismatch repair.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients treated in the investigational and control groups?",{"text":118,"@type":114},"The investigational group received neoadjuvant chemotherapy (three cycles of CAPOX or five of FOLFOX) plus surgery and adjuvant chemotherapy, while the control group received upfront surgery followed by adjuvant chemotherapy.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key outcomes of neoadjuvant chemotherapy in the trial?",{"text":122,"@type":114},"Neoadjuvant chemotherapy showed a high completion rate and improved radiologic tumor downstaging and favorable pathologic features, while 2-year disease-free survival was numerically higher but not statistically significant.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363794,1790195672,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ORIGINAL ARTICLE  \nELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer✫  \nJ. Arredondo1 , 2, D. Aliseda3, C. Castañón4, E. Pastor5, P. Tejedor6, M. Muinelo7, C. Pastor8, L. García Flórez9, V. Vigorita10, I. Gallarín11, M. Montoya12, M. Tasende13, F. García14, P. Rodríguez15, A. Ruiz de la Hermosa16, V. Simó15, C. Álvarez17,  \nC. Rodríguez18, J. M. Núñez-Córdoba19 & J. Rodríguez20 ∗, on behalf of the ELECLA trial Collaborative Group‡  \n1Department of Surgery, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona; 2Institute of Health Research of Navarra (IdisNA), Health Department, Goverment of Navarra, Pamplona, Spain; 3Division of General Surgery, Department of Surgery, Stanford University, Stanford, USA; 4Department of Clinical Oncology, Hospital Universitario de León, León; 5Department of Surgery, Hospital Universitario de León, León; 6Department of Surgery, Hospital Universitario Gregorio Marañon, Madrid; 7Department of Surgery, Hospital Universitario Lucus Augusti, Lugo; 8Department of Surgery, Cancer Center Clínica Universidad de Navarra (CCUN), Madrid; 9Department of Surgery, Hospital Universitario Central de Asturias, ISPA (Instituto de Investigación Sanitaria del Principado de Asturias), Oviedo; 10Department of Surgery, Hospital Universitario de Vigo, Vigo; 11Department of Surgery, Hospital Universitario de Badajoz, Badajoz; 12Department of Surgery, Hospital Universitario Virgen de la Arrixaca, Murcia; 13Department of Surgery, Hospital Universitario Son Llàtzer, Palma de Mallorca; 14Department of Surgery, Hospital Universitario Nuestra Señora del Prado, Talavera de la Reina; 15Department of Surgery, Hospital Universitario Río Hortega, Valladolid; 16Department of Surgery, Hospital Universitario Infanta Leonor, Madrid; 17Department of Pathology, Hospital Universitario de León, León; 18Department of Radiology, Hospital Universitario de León, León; 19Research Support Service, Department of Clinical Trials, Cancer Center Clínica Universidad de Navarra, Pamplona; 20Department of Clinical Oncology, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain  \nAvailable online xxx  \nBackground: The current standard of care for resectable locally advanced colon cancer (LACC) is based on upfront surgery followed by adjuvant chemotherapy (AC) . This study aimed to evaluate the safety and efficacy of neoadjuvant chemotherapy (NAC) in this setting.  \nPatients and methods: ELECLA is a multicenter, randomized, open-label, phase II controlled trial conducted across 12 hospitals in Spain between March 2017 and June 2024. This report presents the results of a preplanned interim analysis conducted after early termination of recruitment following the loss of clinical equipoise. Patients with radiologically defined LACC (T3 > 5 mm/T4, any N, and M0) and proficient mismatch repair status, were randomly assigned at a 1:1 ratio to receive either NAC (three cycles of CAPOX or five of FOLFOX), surgery, and AC (investigational group) or upfront surgery followed by AC (control group) . The primary endpoint was 2-year disease-free survival.  \nResults: A total of 120 patients were included. The NAC completion rate was 94.2%, with a nonsignificant trend toward a reduced surgical complication rate compared with controls (17 .3% versus 22. 1%; P = 0.52) . In the investigational group, a favorable radiologic tumor downstaging was achieved, with a tumor volume reduction of 65 .4%(P \u003C 0.001), and a tumor regression grading of 0-2 in 51.2% of assessable patients. An R0 resection was achieved in all patients within the NAC group. A relevant reduction in classical histological adverse prognostic features, including lymphatic invasion (21 .5% versus 44. 1%; P = 0.009), tumor budding (23 .3% versus 58.5%; P = 0.002), and incomplete resections (0% versus 7.4%; P = 0.068) was observed in the NAC group. The 2-year disease-free survival rate w","cbCaiolY3fZkW9LU","https://ap.wps.com/l/cbCaiolY3fZkW9LU","pdf",896458,11,"English","# Background\n# Patients and methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What was the ELECLA trial designed to assess in locally advanced colon cancer?\",\"answer\":\"It evaluated the safety and efficacy of neoadjuvant chemotherapy versus upfront surgery followed by adjuvant chemotherapy in radiologically defined locally advanced colon cancer with proficient mismatch repair.\"},{\"question\":\"How were patients treated in the investigational and control groups?\",\"answer\":\"The investigational group received neoadjuvant chemotherapy (three cycles of CAPOX or five of FOLFOX) plus surgery and adjuvant chemotherapy, while the control group received upfront surgery followed by adjuvant chemotherapy.\"},{\"question\":\"What were the key outcomes of neoadjuvant chemotherapy in the trial?\",\"answer\":\"Neoadjuvant chemotherapy showed a high completion rate and improved radiologic tumor downstaging and favorable pathologic features, while 2-year disease-free survival was numerically higher but not statistically significant.\"}]","ELECLA trial - final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer | PDF",1790153188,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e7d75dce230508c2a3d8ddb8d37fba5.webp",983,1269,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1289723c871f2c1068723636a5c44fed.webp",982,1268,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc356a199ae561df89403f95a41bddf2.webp",981,1266,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa927ee3980126b65f743e1fb7f01f40.webp",980,1265]